These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23530930)

  • 1. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD.
    Takahashi K; Kantarjian H; Pemmaraju N; Andreeff M; Borthakur G; Faderl S; Garcia-Manero G; Pierce S; Luthra R; Cardenas-Turanzas M; Estrov Z; Ravandi F; Cortes J
    Br J Haematol; 2013 Jun; 161(5):659-666. PubMed ID: 23530930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
    Yilmaz M; Alfayez M; DiNardo CD; Borthakur G; Kadia TM; Konopleva MY; Loghavi S; Kanagal-Shamanna R; Patel KP; Jabbour EJ; Garcia-Manero G; Pemmaraju N; Pierce SA; Ghayas I; Short NJ; Montalban-Bravo G; Takahashi K; Assi R; Alotaibi AS; Ohanian M; Andreeff M; Cortes JE; Kantarjian HM; Ravandi F; Daver NG
    J Hematol Oncol; 2020 Oct; 13(1):132. PubMed ID: 33032648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.
    Schwartz GW; Manning B; Zhou Y; Velu P; Bigdeli A; Astles R; Lehman AW; Morrissette JJD; Perl AE; Li M; Carroll M; Faryabi RB
    Clin Cancer Res; 2019 Jan; 25(2):573-583. PubMed ID: 30181385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
    Sharma M; Ravandi F; Bayraktar UD; Chiattone A; Bashir Q; Giralt S; Chen J; Qazilbash M; Kebriaei P; Konopleva M; Andreeff M; Cortes J; McCue D; Kantarjian H; Champlin RE; de Lima M
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1874-7. PubMed ID: 21767516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
    Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
    Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
    Ganguly S; Cortes JE; Krämer A; Levis MJ; Martinelli G; Perl AE; Russell NH; Arunachalam M; Santos CD; Gammon G; Lesegretain A; Mires DE; Pham H; Wang Y; Khaled SK
    Transplant Cell Ther; 2021 Feb; 27(2):153-162. PubMed ID: 33017662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.
    Brunner AM; Li S; Fathi AT; Wadleigh M; Ho VT; Collier K; Connolly C; Ballen KK; Cutler CS; Dey BR; El-Jawahri A; Nikiforow S; McAfee SL; Koreth J; Deangelo DJ; Alyea EP; Antin JH; Spitzer TR; Stone RM; Soiffer RJ; Chen YB
    Br J Haematol; 2016 Nov; 175(3):496-504. PubMed ID: 27434660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
    Cortes JE; Khaled S; Martinelli G; Perl AE; Ganguly S; Russell N; Krämer A; Dombret H; Hogge D; Jonas BA; Leung AY; Mehta P; Montesinos P; Radsak M; Sica S; Arunachalam M; Holmes M; Kobayashi K; Namuyinga R; Ge N; Yver A; Zhang Y; Levis MJ
    Lancet Oncol; 2019 Jul; 20(7):984-997. PubMed ID: 31175001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.
    Metzelder S; Wang Y; Wollmer E; Wanzel M; Teichler S; Chaturvedi A; Eilers M; Enghofer E; Neubauer A; Burchert A
    Blood; 2009 Jun; 113(26):6567-71. PubMed ID: 19389879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
    Cortes JE; Kantarjian H; Foran JM; Ghirdaladze D; Zodelava M; Borthakur G; Gammon G; Trone D; Armstrong RC; James J; Levis M
    J Clin Oncol; 2013 Oct; 31(29):3681-7. PubMed ID: 24002496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.
    Xuan L; Wang Y; Huang F; Jiang E; Deng L; Wu B; Fan Z; Liang X; Xu N; Ye J; Lin R; Yin C; Zhang Y; Sun J; Han M; Huang X; Liu Q
    Cancer; 2018 May; 124(9):1954-1963. PubMed ID: 29509276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gilteritinib or Chemotherapy for Relapsed or Refractory
    Perl AE; Martinelli G; Cortes JE; Neubauer A; Berman E; Paolini S; Montesinos P; Baer MR; Larson RA; Ustun C; Fabbiano F; Erba HP; Di Stasi A; Stuart R; Olin R; Kasner M; Ciceri F; Chou WC; Podoltsev N; Recher C; Yokoyama H; Hosono N; Yoon SS; Lee JH; Pardee T; Fathi AT; Liu C; Hasabou N; Liu X; Bahceci E; Levis MJ
    N Engl J Med; 2019 Oct; 381(18):1728-1740. PubMed ID: 31665578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.
    Giri S; Hamdeh S; Bhatt VR; Schwarz JK
    J Natl Compr Canc Netw; 2015 May; 13(5):508-14. PubMed ID: 25964636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
    Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
    Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in
    Cortes JE; Tallman MS; Schiller GJ; Trone D; Gammon G; Goldberg SL; Perl AE; Marie JP; Martinelli G; Kantarjian HM; Levis MJ
    Blood; 2018 Aug; 132(6):598-607. PubMed ID: 29875101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.
    Daver N; Venugopal S; Ravandi F
    Blood Cancer J; 2021 May; 11(5):104. PubMed ID: 34045454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
    De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F
    Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation.
    Xuan L; Wang Y; Chen J; Jiang E; Gao L; Wu B; Deng L; Liang X; Huang F; Fan Z; Tang X; Sun J; Zhang X; Han M; Wu D; Huang X; Liu Q
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1674-1681. PubMed ID: 31009704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.
    Brunet S; Labopin M; Esteve J; Cornelissen J; Socié G; Iori AP; Verdonck LF; Volin L; Gratwohl A; Sierra J; Mohty M; Rocha V
    J Clin Oncol; 2012 Mar; 30(7):735-41. PubMed ID: 22291086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.